Abstract | PURPOSE: DESIGN: This retrospective observational study involved 19 previously untreated patients with BRVO. Aqueous humor was obtained, and intravitreal ranibizumab (IVR) injection was administered to these patients. The correlation between VEGF and flare, central retinal thickness (CRT), and best-corrected visual acuity (BCVA) was investigated. Differences in these values were considered between pre-IVR and 1 week and 1-3 months post-IVR. Moreover, in patients with recurrence who received additional IVR, further changes in VEGF were examined. MAIN OUTCOME MEASURES: The end point of this study was BCVA, flare, and CRT at the fovea. RESULTS: Significant improvement was seen in BCVA and CRT at all time points and in Flare at 1 vs 3 months post-IVR; nevertheless, additional IVR was necessary in 94% of cases. In a patient with recurrence, CRT did not improve, even though VEGF decreased. CONCLUSION: Flare may be effective for estimating VEGF levels in aqueous humor pre-IVR. Inflammation-related molecules other than VEGF may be related to recurrence.
|
Authors | Hideaki Okawada, Yuta Saito, Shigehiro Iwabuchi, Shotaro Kosuge, Haruo Takahashi, Hidetoshi Onda, Masahiro Kito |
Journal | Clinical ophthalmology (Auckland, N.Z.)
(Clin Ophthalmol)
Vol. 12
Pg. 1379-1382
( 2018)
ISSN: 1177-5467 [Print] New Zealand |
PMID | 30122890
(Publication Type: Journal Article)
|